Enrichment Factors for Clinical Trials in Mild-to-Moderate Alzheimer’s Disease

Authors

Clive Ballard, University of Exeter Medical School
Alireza Atri, Banner Sun Health Research Institute
Neli Boneva, Lundbeck A/S
Jeffrey L. Cummings, University of Nevada, Las VegasFollow
Lutz Frolich, University of Heidelberg
Jose Luis Molinuevo, Barcelona Brain Research Center
Pierre N. Tariot, Cleveland Clinic Lou Ruvo Center for Brain Health
Lars Lau Raket, Lundbeck A/S

Document Type

Article

Publication Date

1-1-2019

Publication Title

Alzheimer’s and Dementia

Volume

5

First page number:

164

Last page number:

174

Abstract

Heterogeneity of outcomes in Alzheimer’s disease (AD) clinical trials necessitates large sample sizes and contributes to study failures. This analysis determined whether mild-to-moderate AD populations could be enriched for cognitive decline based on apolipoprotein (APOE)ε4 genotype, family history of AD, and amyloid abnormalities.

Keywords

Alzheimer’s disease; Clinical trial; Enrichment; Power; Biomarkers

Disciplines

Medicine and Health Sciences

Language

English

Repository Citation

Ballard, C., Atri, A., Boneva, N., Cummings, J. L., Frolich, L., Molinuevo, J., Tariot, P. N., Raket, L. (2019). Enrichment Factors for Clinical Trials in Mild-to-Moderate Alzheimer’s Disease. Alzheimer’s and Dementia, 5 164-174.
http://dx.doi.org/10.1016/j.trci.2019.04.001